"Through our strategy, we have consistently demonstrated our capability for serial innovation," says Arbuckle. “If we want to keep up that pace of innovation it’s critical we maintain our focus.” Given that the company has pioneered the first medications that target the underlying cause of cystic fibrosis, and is at the forefront of utilizing groundbreaking technologies like CRISPR/Cas9 and encapsulated cell therapies, it’s hard to argue with Arbuckle's point.

‍

Read more >>

‍